quinazolines has been researched along with arq 197 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adjei, AA; Garmey, E; Schwartz, B | 1 |
| Akerley, WL; Arthur, S; Brugger, W; Chen, Y; Costa, DB; Ferrari, D; Garmey, EG; Gerber, DE; Gorbachevsky, I; Orlov, S; Ramlau, R; Schiller, JH; Schwartz, B; Sequist, LV; von Pawel, J | 1 |
| Hirsh, V; Novello, S; Sandler, AB; Scagliotti, GV; Schiller, JH; Schwartz, B; Sequist, LV; Soria, JC; von Pawel, J; Von Roemeling, R | 1 |
| Chai, F; Ferrari, D; Garmey, EG; Goldman, JW; Just, RG; Laux, I; Rosen, LS; Savage, RE | 1 |
| Brierley, R | 1 |
| Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW | 1 |
| Akinaga, S; Fujisaka, Y; Hayashi, H; Hirashima, T; Miyoshi, K; Murakami, H; Nakagawa, K; Satouchi, M; Takahashi, T; Takeda, K; Yamamoto, N | 1 |
| Nakagawa, T; Yano, S | 1 |
| Liu, C; Qu, G; Sun, B; Wang, P; Zhang, Z; Zhou, C | 1 |
| Akerley, W; Barlesi, F; Favaretto, A; Hirsh, V; Novello, S; Orlov, S; Ramlau, R; Ross, JS; Sandler, A; Santoro, A; Scagliotti, G; Schwartz, B; Sequist, LV; Shepherd, FA; Shuster, D; Spigel, D; von Pawel, J; von Roemeling, R; Wang, Q | 1 |
1 review(s) available for quinazolines and arq 197
| Article | Year |
|---|---|
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation | 2013 |
5 trial(s) available for quinazolines and arq 197
| Article | Year |
|---|---|
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Growth Factor; Survival Analysis | 2011 |
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Research Design; Salvage Therapy; Survival Rate | 2012 |
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2012 |
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Disease Progression; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2013 |
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pyrrolidinones; Quinazolines; Quinolines; Young Adult | 2015 |
4 other study(ies) available for quinazolines and arq 197
| Article | Year |
|---|---|
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor | 2011 |
14th World Congress on Gastrointestinal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neoplasms; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Fluorouracil; Genotype; Humans; Molecular Targeted Therapy; Pharmacogenetics; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2012 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2014 |